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Purpose: Despite improved clinical outcomes for the
majority of patients, nearly 30% of patients with rheu-
matoid arthritis (RA) who initiate tumor necrosis factor
antagonist (anti-TNF) biologic agents fail to respond to
their ﬁrst-line anti-TNF and switch to another anti-TNF
or a non-TNF biologic. How this change affects health
care costs and resource utilization is unknown. We
therefore compared RA patients taking ﬁrst-line anti-
TNFs who switched to a second anti-TNF versus those
patients who switched to an alternate biologic.
Methods: Health care claims data were obtained
from a large US database for eligible adults with
conﬁrmed RA diagnoses who initiated anti-TNF treat-
ment and switched to another biologic. Health care
costs and utilization during the ﬁrst 12 months’
postswitch were compared. Generalized linear models
were used to adjust for differences in demographic
and clinical characteristics before switching.
Findings: Patients who switched to a second anti-TNF
rather than a non-TNF biologic were generally younger
(53.0 vs. 55.3 years; P o 0.0001) and less likely to be
female (79.7% vs. 82.7%; P ¼ 0.0490). Of the 3497
eligible patients who switched from ﬁrst-line anti-TNFs,
2563 (73.3%) switched to another anti-TNF and 934
(26.7%) switched to a non-TNF. Adalimumab was the
most frequently prescribed (43.4%) second-line anti-TNF,
and abatacept was the most common non–anti-TNF
(71.4%). Patients who switched to a second anti-TNF
remained on their ﬁrst medication for a signiﬁcantly
shorter period (342.5 vs 420.6 days; P o 0.0001) and
had lower comorbidity indices and higher disease severity
at baseline than those who switched to a non–anti-TNF.
After adjusting for baseline differences, patients who
switched to second anti-TNFs versus a non-TNF incurred1454lower RA-related costs ($20,938.9 vs $22,645.2; P ¼
0.0010) and total health care costs ($34,894.6 vs
$38,437.2; P ¼ 0.0010) 1 year postswitch. These differ-
ences were driven by increased physician ofﬁce visit costs
among the non-TNF group.
Implications: Among the anti-TNF initiators who
switched therapy, more patients switched to a second
anti-TNF than to a non-TNF. Switching to a second anti-
TNF treatment was associated with lower all-cause and
RA-related health care costs and resource utilization than
switching to a non-TNF. Because switching therapy may
be unavoidable, ﬁnding a treatment algorithm mitigating
this increase to any extent should be considered. These
data are limited by their retrospective design. Additional
confounding variables that could not be controlled
for may affect results. (Clin Ther. 2015;37:1454–1465)
& 2015 The Authors. Published by Elsevier HS Journals,
Inc.
Key words: health care costs, health care utiliza-
tion, rheumatoid arthritis, real-world data analysis.INTRODUCTION
Rheumatoid arthritis (RA) is an autoimmune disorder
causing joint pain and swelling that progresses to joint
tissue and bone destruction.1 The prevalence of RA is
estimated at 1.5 million adults in the United States,
which has signiﬁcant economic implications for both
individual patients and society.2 Each year, RA isVolume 37 Number 7
O. Baser et al.responsible for 4250,000 hospitalizations and 49
million physician visits in addition to a decrease in life
expectancy of 3 to 10 years.3,4 Moreover, excess health
care costs for patients with RA in the United States have
been estimated at $8.4 billion annually, with an addi-
tional $10.9 billion lost due to functional and work
limitations (prices in 2005 US dollars).5 Appropriate
pharmacy and medical policies for the management of
patients with RA based on clinical and economic data are
imperative for improving patient outcomes while
controlling health care costs at the population level.
In the past decade, tumor necrosis factor antagonist
(anti-TNF) use has changed the treatment paradigm,
with improved clinical outcomes for RA patients with
moderate to severe disease.6 Anti-TNF combination
therapy with methotrexate (MTX) has been shown to
be a cost beneﬁt, compared with conventional disease-
modifying antirheumatic drug therapy, and has dem-
onstrated slowing of radiographic progression.7
However, nearly 30% of patients with RA fail to
respond to their ﬁrst anti-TNF agent or experience
adverse events by 2 years of therapy.8 Subsequent
therapeutic options include switching to another anti-
TNF or to a non-TNF biologic agent.
The availability of multiple biologic agents has
engendered the question of whether switching to a
different TNF inhibitor versus switching to a non-TNF
biologic will lead to different clinical and economic
outcomes after failure to respond to the initial anti-TNF.
Several managed-care medical policies require treatment
with at least 2 TNF inhibitors before switching to an
alternate biologic agent.9 These policies are based on the
results of controlled clinical trials and observational
studies that have shown beneﬁt for a number of
patients who failed to respond to initial anti-TNF
therapy and who switched to another TNF inhibi-
tor.10–13 In these studies, patients were more likely to
respond to a subsequent anti-TNF agent if previous anti-
TNF treatment was discontinued because of adverse
reactions.14,15 Although there are controlled clinical
trials evaluating the efﬁcacy and safety of non-TNF
biologic agents in patients who have failed to respond to
anti-TNF therapy, there are few head-to-head studies
that directly compare switching to a second anti-TNF
versus switching to a non-TNF biologic agent.16–18
A recent study of observational data from the Con-
sortium of Rheumatology Researchers of North America,
Inc. (CORRONA) RA registry, which enrolls RA patients
from private and academic institutions across the UnitedJuly 2015States, found that clinical outcomes after a switch from
one TNF inhibitor to a second TNF inhibitor were similar
to those observed when switching to abatacept (ABA).19
Although this study evaluated clinical outcomes in an
observational setting, an economic evaluation was not
conducted. The latter is an important issue because the
cost-effectiveness associated with switching to a second-
line biologic agent is poorly deﬁned, although studies
have shown that, after a switch in treatment, patients
incur higher costs compared with those who do not
switch.20,21 It is possible that both clinical and economic
evaluation of biologic switching may guide policy devel-
opment to ensure this disabling disease is controlled at the
population level while managing overall health care costs.
The objective of the present study, therefore, was to
evaluate the impact on health care costs and resource
utilization of switching from a ﬁrst-line anti-TNF therapy
to a second biologic agent. We also examined whether
there was a differential impact on cost and resource
utilization associated with switching to a second anti-
TNF agent compared with switching to a non-TNF
antagonist.
PATIENTS AND METHODS
Data Source
The Truven Health MarketScan Commercial
Claims and Encounters Database and the Medicare
Supplemental and Coordination of Beneﬁts database
from January 2004 through December 2010 were
used in this retrospective study. These databases
capture the full continuum of care in all settings,
including physician ofﬁce visits, inpatient stay, emer-
gency department (ED) visits, and retail, mail order,
and specialty pharmacy claims, as well as patient
demographic and enrollment information.
Study Sample
Adult patients at least 18 years of age with at least
2 physician-conﬁrmed diagnoses of RA (International
Classiﬁcation of Diseases, Ninth Revision, Clinical
Modiﬁcation, code: 714.0X) at least 2 months apart
during the identiﬁcation period (January 2005–
December 2009) were selected.22 Patients were
required to have an initial prescription claim for an
anti-TNF biologic (etanercept [ETN], adalimumab
[ADA], or inﬂiximab [IFX]) after RA diagnosis and a
subsequent switch to another anti-TNF (ETN, ADA,
IFX, golimumab, or certolizumab) or non-TNF biologic
(ABA, anakinra [ANK], or rituximab). Tocilizumab,1455
Clinical Therapeuticsapproved in January 2010, was not included in
this study.
Patients were considered to have switched therapy
if they had been prescribed another anti-TNF or non-
TNF biologic agent without successive claims of the
initial biologic agent. A minimum 12-month biologic-
free period was required before the ﬁrst anti-TNF
agent. In addition, all patients in this study were
required to have at least 12 months of continuous
medical and pharmacy beneﬁts before the ﬁrst anti-
TNF claim date and for 12 months after the switch
date. The switch date was designated as the index
date. All baseline variables were calculated for the 12
months before the index date (baseline period), and
outcome variables were calculated for the 12 months
after the index date (follow-up period).
Informed Consent
No patient identity or medical records were dis-
closed for the purposes of this study except in
compliance with applicable law. Because the core
study proposed herein does not involve the collection,
use, or transmittal of individual identiﬁable data,
patient approval/consent to conduct this study was
not required.
Cohort Assignments
To compare patients who switched to another
anti-TNF biologic versus those who switched to a
non–anti-TNF biologic, 2 cohorts were created. The
anti-TNF biologic switcher cohort consisted of patients
who initiated ETN, ADA, or IFX and later switched to
ETN, ADA, IFX, golimumab, or certolizumab. The
non-TNF biologic switcher cohort was composed of
patients who initiated ETN, ADA, or IFX and later
switched to ABA, anakinra, or rituximab.
Baseline Covariates
Demographic variables included age, sex, geo-
graphic region, index year, and health plan type.
Baseline comorbidity measures included the Charlson
Comorbidity Index (CCI) score,23,24 Chronic Disease
Score,25 binary indicator of Elixhauser index score
42,26 individual comorbidities such as scleroderma,
ﬁbromyalgia, Crohn’s disease, respiratory disease,
respiratory infection, and baseline Severity Index for
Rheumatoid Arthritis (SIFRA; STATinMED Research,
Ann Arbor, MI) score.27 SIFRA was developed by
calculating a weighted sum of 34 RA-related1456indicators, including clinical and functional status,
extra-articular manifestations, surgical history, and
medications, assessed by an expert Delphi panel of 6
rheumatologists.28 Higher SIFRA scores indicate
increased disease severity, and the Elixhauser index
has shown evidence of being a signiﬁcant determinant
of total and RA-related health care costs for patients
with RA.26
Other baseline measures included RA-related treat-
ments such as NSAIDs, corticosteroids, xenobiotics,
MTX, and cytotoxic therapy. Baseline health care
costs (including total all-cause pharmacy, knee and
hip replacement surgery, laboratory tests, hospital-
ization, and ED and physician ofﬁce visit costs) were
also measured. Physician prescribing patterns were
calculated as the percentage of times the ﬁrst-line anti-
TNF biologic agent was prescribed. Days from the
ﬁrst anti-TNF claim to the index date were calculated
to determine the time to therapy switch.
Outcome Variables
Total all-cause health care costs, in addition to those
associated with pharmacy, knee and hip replacement
surgery, laboratory tests, hospitalization, and ED and
physician ofﬁce visits, were calculated for the 12-
month follow-up period. Total RA-related health care
costs were calculated by using medical claims with an
RA diagnosis claim in any position. RA-related phar-
macy costs were calculated for anti-TNF, NSAIDs,
corticosteroid, xenobiotic, cytotoxic therapy, and
MTX pharmacy claims. Health care costs were calcu-
lated on the basis of the amount paid by the health
care plan for relevant claims and the net cost of any
patient contribution (eg, copayment). Costs are ex-
pressed in 2012 US dollars and were adjusted by using
the medical care component of the US Consumer Price
Index. For health care utilization estimates, the number
and binary indicator of hospitalizations, ED visits, and
physician ofﬁce visits were calculated for the follow-up
period. The follow-up period SIFRA score, which was
validated by using a large claims database,27 was used
to measure disease severity.
Statistical Analysis
Descriptive and bivariate analyses were performed
for the anti-TNF and non-TNF switcher cohorts for
baseline and outcome variables. Percentages and SDs
were calculated for dichotomous variables, and means
and SDs were calculated for continuous variables.Volume 37 Number 7
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Student t test for dichotomous and continuous varia-
bles, respectively.
Multivariate analysis was performed by using a
generalized linear model, in which log link and gamma
distributions were used for cost outcomes, negative
binomial distribution was used for count variables (eg,
number of health care utilization visits), and logistic
distribution was used for binary outcomes (eg, having
at least 1 visit). Variables included in the model were
age, sex, geographic region, health care plan type,
index year, index copay, baseline CCI score, Chronic
Disease Score, Elixhauser index score, other individual
comorbidities, physician prescribing patterns, baseline
RA therapies, and health care utilizations and costs.
Descriptive and multivariate results were compared
between the anti-TNF biologic switcher cohort and the
non-TNF biologic switcher cohort.
RESULTS
A total of 234,483 patients were identiﬁed for in-
clusion in the study during the identiﬁcation period
(January 2005–December 2009). Of these, 3497
patients met inclusion criteria for the ﬁnal study
sample, with 44.0% (n ¼ 1540) initiating treatment
with ETN, 36.2% (n ¼ 1265) with ADA, and 19.8%
(n ¼ 692) with IFX. Within this population, 2563
patients (73.3%) switched to a second anti-TNF
biologic, and 934 patients (26.7%) switched to a
non-TNF biologic (Figure 1).
Among the 1540 patients who initiated ETN,
81.6% (n ¼ 1257) switched to another anti-TNF
biologic, most commonly ADA (74.9% [n ¼ 942]).
Similarly, 77.2% (n ¼ 976) of the 1265 patients who
initiated therapy with ADA switched to another anti-
TNF biologic, of which ETN (67.1% [n ¼ 655]) was
the most common. Patients who initiated therapy with
IFX (n ¼ 692) were more likely to switch to a non-
TNF biologic (52.3% [n ¼ 362]). ADA was the most
frequently prescribed second anti-TNF agent (43.4%
[n ¼ 1111]) among patients switched to an anti-TNF
(n ¼ 2563). ABA was the most common non-TNF
biologic prescribed (71.4% [n ¼ 667]) among patients
switched to a non-TNF biologic (n ¼ 934) (Figure 2).
Baseline Demographic and Clinical
Characteristics
Patients who switched to a second anti-TNF rather
than a non-TNF biologic were generally youngerJuly 2015(53.0 vs 55.3 years; P o 0.0001) and less likely to
be female (79.7% vs 82.7%; P ¼ 0.0490) (Table I).
The time to switch from one anti-TNF to another was
shorter compared with switching to a non-TNF bio-
logic (342.5 vs 420.6 days; P o 0.0001). In addition,
patients who switched to a second anti-TNF were
more likely to have an initial prescription for ETN
(49.0% vs 30.3%; P o 0.0001) or ADA (38.1% vs
30.9%; P ¼ 0.0001) than IFX (12.9% vs 38.8%; Po
0.0001), compared with those who switched to a non-
TNF biologic (Table II).
During the baseline period, patients who switched
to a second anti-TNF compared with a non-TNF
biologic had higher SIFRA scores (4.5 vs 4.3; P ¼
0.0004), lower CCI scores (2.0 vs 2.5; P o 0.0001),
and a lower percentage with Elixhauser index scores
42 (14.6% vs 20.9%; P o 0.0001) (Table II). In
terms of RA-related medication and therapies, anti-
TNF switchers were less likely to be prescribed
corticosteroids (73.5% vs 76.9%; P ¼ 0.0436) but
more likely to be prescribed MTX (64.1% vs 57.4%;
P ¼ 0.0003) compared with non-TNF switchers.
The initial route of administration also played a
signiﬁcant role in the switching methods. Those who
were initially taking a subcutaneous anti-TNF biologic
(eg, ETN, ADA) were more likely to receive a
subsequent anti-TNF agent. In contrast, those who
were initially treated with an infused anti-TNF (IFX)
were more likely to be treated with a non-TNF versus
a second anti-TNF biologic (25.4% vs 23.7%; P ¼
0.004).
Baseline Health Care Costs
During the 12 months before switching therapy, anti-
TNF biologic switchers incurred lower total health care
costs than non-TNF biologic switchers ($23,088.4 vs
$31,108.0; Po 0.0001). Of the cost categories evaluated,
hospitalization ($2788.4 vs $6229.1; P ¼ 0.0003),
laboratory tests ($543.1 vs $656.6; P ¼ 0.0050),
pharmacy ($12,652.5 vs $13,747.7; P ¼ 0.0036), and
physician ofﬁce visits ($1480.9 vs $1798.0; Po 0.0001)
costs were lower in the anti-TNF group (Table III).Risk-Adjusted Outcomes
After controlling for baseline demographic and
clinical differences by using a generalized linear
model, anti-TNF biologic switchers incurred signiﬁ-
cantly lower all-cause costs ($34,894.6 vs $38,437.2;1457
≥2 RA diagnoses (ICD-9-CM: 714.0x) ≥60 days apart during identification
period (January 2005–December 2009) (N = 234,483)
≥18 years of age at time of first diagnosis
(n = 233,065)
Initiated IFX, ETN, or ADA after RA diagnosis during
the identification period (n = 71,335)
Have a 12-month “clean” period before initiation
of first anti-TNF (n = 37,533)
Switched to another anti-TNF/non-TNF biologic
during the identification period (n = 5950)
Continuous enrollment 12 months before initiation of first anti-
TNF and 12 months after index date (first switch date) (n = 3497)
Switched to anti-TNF biologic
(n = 2563)
Switched to non-TNF biologic
(n = 934)
Figure 1. Subject identification. RA ¼ rheumatoid arthritis; ICD-9-CM ¼ International Classification of Diseases,
Ninth Revision, Clinical Modification; IFX ¼ infliximab; ETN ¼ etanercept; ADA ¼ adalimumab; TNF ¼
tumor necrosis factor.
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Figure 2. Patient switching pattern from first tumor necrosis factor antagonist (anti-TNF). ETN ¼ etanercept;
ADA ¼ adalimumab; IFX ¼ infliximab; GLM ¼ golimumab; CZP ¼ certolizumab pegol; ABA ¼
abatacept.
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Table I. Baseline demographic characteristics of tumor necrosis factor antagonist (anti-TNF) biologic
switcher and non-TNF biologic switcher cohorts.
Characteristic
Anti-TNF Switcher Cohort
(n ¼ 2563)
Non-TNF Switcher Cohort
(n ¼ 934) P
Age, y* 53.0 (12.1) 55.3 (12.7) o0.0001
Female sex 2042 (79.7%) 772 (82.7%) 0.0490
Geographic region
Northeast 237 (9.3%) 65 (7.0%) 0.0331
North-central 635 (24.8%) 251 (26.9%) 0.2069
South 1146 (44.7%) 438 (46.9%) 0.2515
West 533 (20.8%) 176 (18.8%) 0.2039
Unknown 12 (0.5%) 4 (0.4%) 0.8770
Years of trigger
2005 99 (3.9%) 6 (0.6%) o0.0001
2006 334 (13.0%) 96 (10.3%) 0.0283
2007 556 (21.7%) 177 (19.0%) 0.0779
2008 781 (30.5%) 358 (38.3%) o0.0001
2009 793 (30.9%) 297 (31.8%) 0.6278
Time to switch, d* 342.5 (291.1) 420.6 (311.0) o0.0001
*Mean (SD).
O. Baser et al.P ¼ 0.0010) and RA-related health care costs
($20,938.9 vs $22,645.2; P ¼ 0.0010) compared with
non-TNF biologic switchers during the follow-up
period (Figure 3).
Total pharmacy (including non-TNF, anti-TNF,
and all outpatient pharmacy costs), knee and hip
replacement surgery, hospitalization, laboratory tests,
and ED visit costs were similar for anti-TNF biologic
switchers and non-TNF biologic switchers. However,
anti-TNF biologic switchers had fewer physician ofﬁce
visits (15.0 vs 19.3; P o 0.0010), which translated
into lower associated costs ($1535.1 vs $1993.6; P o
0.0010) (Table IV). In addition, anti-TNF biologic
switchers incurred signiﬁcantly lower RA-related costs
compared with non-TNF biologic switchers during the
follow-up period.
DISCUSSION
Several studies have found that patients with RA who
switch to a second biologic agent of any mechanism
incur higher medical costs both before and after the
switch compared with patients who continue treat-
ment with their initial biologic agent.20,21,29 One large
retrospective claims analysis reported that baselineJuly 2015monthly health care costs were 27% higher for
patients who switched ﬁrst-line biologic therapy com-
pared with nonswitchers.21 This study also found that
postswitching costs were increased by 35% for ﬁrst-
line biologic switchers versus nonswitchers, after
controlling for potential confounders. Together, these
data indicate that switching biologic therapy is asso-
ciated with increased costs.
The present study found that numeric costs were
higher in the 12 months after a switch from a TNF
inhibitor to a non-TNF compared with a second anti-
TNF. Although speciﬁc reasons for the switch were
not evaluable in this study, switching patterns seemed
to be based on the initial prescription. Of patients who
were initiated on a self-injectable biologic (ADA or
ETN), approximately three quarters were switched to
another subcutaneously administered anti-TNF. How-
ever, 50% of those initiated on IFX were switched to
an agent with an alternate mechanism of action. The
difference in costs could not be explained by differ-
ences in patient characteristics at the time of the
switch. Those switched to a non-TNF were more
likely to be female, to be older, and to have more
comorbidities than those who did not switch.1459
Table II. Clinical characteristics at point of switch of tumor necrosis factor antagonist (anti-TNF) and non-
TNF biologic switcher cohorts.
Characteristic
Anti-TNF Switcher Cohort
(n ¼ 2563)
Non-TNF Switcher Cohort
(n ¼ 934) P
Initial TNF
ETN 1257 (49.0%) 283 (18.4%) o0.0001
ADA 976 (38.1%) 289 (22.8%) 0.0001
IFX 330 (12.9%) 362 (52.3%) o0.0001
SIFRA score* 4.5 (1.2) 4.3 (1.2) 0.0004
Baseline comorbidities
Charlson Comorbidity Index score* 2.0 (1.4) 2.5 (1.9) o0.0001
Elixhauser index score 42 375 (14.6%) 195 (20.9%) o0.0001
Chronic Disease Score* 7.2 (3.6) 7.4 (3.7) 0.1178
Baseline comorbidities
Scleroderma 4 (0.2%) 2 (0.2%) 0.7136
Fibromyalgia 221 (8.6%) 75 (8.0%) 0.5774
Crohn’s disease 34 (1.3%) 6 (0.6%) 0.0923
Respiratory disease 1232 (48.1%) 513 (54.9%) 0.0003
Respiratory infection 890 (34.7%) 350 (37.5%) 0.1328
Baseline RA-related therapies
NSAIDs 2058 (80.3%) 762 (81.6%) 0.3937
Corticosteroids 1884 (73.5%) 718 (76.9%) 0.0436
Xenobiotics 724 (28.3%) 252 (27.0%) 0.4597
Methotrexate 1644 (64.1%) 536 (57.4%) 0.0003
Cytotoxic therapy 559 (21.8%) 230 (24.6%) 0.0781
% Physician-prescribing patterns*
ETN 19.4 (29.7) 7.9 (19.4) o0.0001
ADA 18.8 (29.2) 8.2 (19.7) o0.0001
IFX 9.8 (23.7) 12.6 (25.4) 0.0040
ETN ¼ etanercept; ADA ¼ adalimumab; IFX ¼ inﬂiximab; SIFRA ¼ Severity Index for Rheumatoid Arthritis; RA ¼
rheumatoid arthritis.
*Mean (SD).
Clinical TherapeuticsInterestingly, the degree of RA disease severity was
lower in those who switched to a non-TNF. The
increased cost of switching to a non-TNF biologic
remained after controlling for these differences. At the
time of our analysis, ABA was available as an intra-
venous infusion administered monthly. Because 70%
of non-TNF switches were to ABA, it is possible that
the increased ofﬁce visit costs and number of visits in
the non-TNF group may be related to the increased
frequency of infusions for ABA compared with IFX
(monthly vs every 8 weeks). As of July 2011, ABA1460became available for subcutaneous administration30;
the 2 administration methods may inﬂuence future
studies evaluating switching from an anti-TNF bio-
logic to a non-TNF biologic.
Few other studies have directly compared anti-TNF
versus non-TNF biologic agents after failure of an
initial biologic. Available data demonstrate that the
reason for switching biologic agents is important in
predicting the chance of treatment success for the
second-line agent.31–34 Efﬁcacy of TNF sequencing is
highest among patients who discontinue their anti-Volume 37 Number 7
Table III. Baseline descriptive health care costs* (mean [SD]) of tumor necrosis factor antagonist (anti-TNF)
biologic switcher and non-TNF biologic switcher cohorts.
Variable
Anti-TNF Biologic Switcher
Cohort, $ (n ¼ 2563)
Non-TNF Biologic Switcher
Cohort, $ (n ¼ 934) P
Total health care 23,088.4 20,069.3 31,108.0 40,832.0 o0.0001
Pharmacy† 12,652.5 8912.3 13,747.7 10,132.9 0.0036
Surgery (knee and hip replacement) 421.9 3778.9 380.6 3640.7 0.7727
Laboratory 543.1 762.4 656.6 1145.2 0.0050
Hospitalization 2788.4 11,913.9 6229.1 28,345.0 0.0003
Emergency department visits 314.9 1240.0 342.5 1058.0 0.5153
Physician ofﬁce visits 1480.9 1310.6 1798.0 2200.1 o0.0001
*Subcategories are those of interest and do not include all costs.
†Costs include all anti-TNF, non-TNF, and outpatient pharmacy costs.
O. Baser et al.TNF agent (owing to tolerability or waning efﬁcacy)
and lower among patients who switch primarily due
to an inadequate response to Z1 agent.8,13,18,35–38
A meta-analysis of 31 studies (incorporating 5306
patients) was conducted; the majority (77%) of the
studies were prospective cohort studies and 1 was a
randomized controlled trial. These studies demon-
strated that efﬁcacy after switching between TNF
inhibitors is lowest after a primary inadequate re-
sponse and an inadequate response to 42 agents.390
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July 2015Evidence from randomized controlled trials also
showed that anti-TNF nonresponders can attain an
efﬁcacious response by switching to a second anti-
TNF agent.11,16,17,40–44 Using data from the COR-
RONA registry, Harrold et al19 directly evaluated the
impact on clinical outcomes of switching to a second
anti-TNF compared with switching to ABA. After
adjusting for a number of previous anti-TNF thera-
pies, baseline disease activity, RA disease severity,
and concomitant medications, clinical outcomes wereTotal RA-related
Health Care Costs*
tis (RA)-related health care costs of tumor necrosis
iologic switcher cohorts during the follow-up period.
1461
Table IV. Risk-adjusted outcomes for tumor necrosis factor antagonist (anti-TNF) biologic switcher and non-
TNF biologic switcher cohorts.
12-Month Follow-up After Switch
Anti-TNF Biologic Switcher
Cohort
Non-TNF Biologic Switcher
Cohort P
Follow-up health care costs, $
Total health care 34,894.6 38,437.2 0.001
Total pharmacy* 21,627.6 21,909.5 0.565
Total surgery (knee and hip
replacement)
550.6 494.6 0.827
Total laboratory 516.6 503.4 0.684
Hospitalization 3522.5 3119.4 0.505
Emergency department visits 297.2 320.5 0.582
Physician ofﬁce visits 1535.1 1993.6 o0.001
Total RA-related 20,938.9 22,645.2 0.001
Total RA-related pharmacy† 18,195.2 18,167.4 0.951
Total RA-related nonpharmacy 2587.0 4341.4 o0.001
Follow-up health care utilizations
No. of hospitalizations 0.3 0.3 0.058
No. of emergency department visits 0.5 0.6 0.174
No. of physician ofﬁce visits 15.0 19.3 o0.001
Hospitalization, % 14.5 17.3 0.147
Emergency department visits, % 28.2 28.9 0.798
Physician ofﬁce visits, % 100.0 100.0 0.999
RA ¼ rheumatoid arthritis.
*Costs include all anti-TNF, non-TNF, and all outpatient pharmacy costs.
†Costs include anti-TNF, non-TNF, corticosteroids, xenobiotics, cytotoxic therapy, and methotrexate.
Clinical Therapeuticssimilar. Schabert et al45 used a health insurance claims
database and a published claims-based algorithm as a
proxy to estimate treatment effectiveness for low
disease activity or remission among RA patients
switching from an anti-TNF to a subsequent anti-
TNF or ABA. Although ABA was slightly more
effective as a second-line biologic than a second anti-
TNF (25% for ABA, 22% for ETN, 21% for ADA,
and 11% for INF), the cost per responder was lower
for both ETN and ADA compared with ABA
($66,449, $71,877, and $87,563, respectively). These
results by Schabert et al may explain the current
ﬁnding of lower all-cause and RA-related health care
costs in the 12 months after a switch to a second TNF
inhibitor compared with a non-TNF biologic.
One strength of the present study is that we
controlled for baseline differences in disease severity.1462SIFRA is a more robust measurement of RA severity
than other comorbidity indices, such as the CCI, the
Elixhauser index, or the Chronic Disease Score.27 The
inclusion of SIFRA improved the strength of our study
and controlled for the important observed bias for
which previous research had not controlled.26 Second,
the present study evaluated the route of administration
for the initial anti-TNF and how this affected what
agent patients received as second-line therapy. The
administration route was found to be strongly related
to the anti-TNF or non-TNF biologic agents to which
patients were switched. In addition, this retrospective
study used a large commercial US claims database and a
7-year observation period, which made it more nation-
ally representative than some previous studies.46–50
There are some limitations to this study, however.
First, because of the retrospective study design, it isVolume 37 Number 7
O. Baser et al.difﬁcult to be certain of causal relationships, and only
the association between the noted variables and out-
comes could be calculated. Second, due to the time
frame in which the study was conducted, all biologic
agents that are currently available for the treatment of
RA were not included in the analysis. There are
additional non-TNF biologic agents available for
subcutaneous administration. Third, due to the nature
of the claims database, the presence of a claim for a
ﬁlled prescription does not indicate whether the
medication was actually used as prescribed. Fourth,
unmeasured confounding variables may have affected
results of the multivariate analysis. For example,
clinical data are not provided in the databases; there-
fore, the reason for treatment failure is unknown.
Patients may switch from an initial anti-TNF biologic
agent because of a lack of efﬁcacy, adverse event/
toxicity, or nonmedical reasons such as cost/insur-
ance, but adjusting for these differences was not
possible in this study. Another important variable to
note is the different approval dates of the biologic
agents, which may inﬂuence prescribing patterns.CONCLUSIONS
The results from the present study indicate that in the
real world, switching to a second anti-TNF was
associated with reduced cost compared with switching
to a non-TNF biologic. Because head-to-head data
directly comparing the clinical efﬁcacy of switching to
a second-line biologic do not consistently support 1
agent over another, using the strategy that results in
the lowest overall cost to the system maybe a prudent
approach in mitigating health care costs. Further
studies are warranted to evaluate biologic switching
and should include reasons for the switch, clinical
outcomes, and cost. This information can assist policy
makers in developing appropriate clinical pathways
that will ensure appropriate disease control while
managing total health care costs.ACKNOWLEDGMENTS
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